Skip Navigation
Skip to contents

CPP : Cardiovascular Prevention and Pharmacotherapy

Sumissioin : submit your manuscript
SEARCH
Search

Author index

Page Path
HOME > Browse articles > Author index
Search
Jang-Whan Bae 2 Articles
Welcome to the New Journal Cardiovascular Prevention and Pharmacotherapy
Mi-Jeong Kim, Jang-Whan Bae, Dae Ryong Kang
Cardiovasc Prev Pharmacother. 2019;1(1):1-2.   Published online July 31, 2019
DOI: https://doi.org/10.36011/cpp.2019.1.e5
  • 785 View
  • 11 Download
PDF
Role of Novel Oral Anticoagulant for Patient with Atrial Fibrillation Underwent Percutaneous Coronary Intervention
Jang-Whan Bae
Cardiovasc Prev Pharmacother. 2019;1(1):19-29.   Published online July 31, 2019
DOI: https://doi.org/10.36011/cpp.2019.1.e1
  • 1,306 View
  • 9 Download
  • 1 Citations
Abstract PDF
Atrial fibrillation (AF) is very common arrhythmic disorder especially in elderly population, and makes higher major adverse cardiac events (MACEs) in the patients with acute coronary syndrome (ACS) or underwent percutaneous coronary intervention (PCI). Pivotal drug for AF patients to reduce systemic embolism was warfarin, and certain duration of dual antiplatelet therapy (DAPT) is important after PCI with stent. But, best regimen of antithrombotic agent after PCI in AF is unclear especially in the clinical use of novel oral anticoagulant (NOAC). This manuscript will deal those clinical studies to indicate optimal regimen and duration of NOAC use for AF patients underwent PCI. NOAC use on DAPT significantly reduces major or minor bleeding compared to warfarin in AF patients with ACS or underwent PCI. But, the duration of NOAC use is still unclear, and there is exist clear contraindication to use it in clinical field. NOAC use reduced major or minor bleeding significantly compared to warfarin, but the incidence of MACEs was similar between warfarin and NOAC. Physician should understand the advantage or disadvantage of NOAC use, and be able to tailor the regimen and duration of antithrombotics including NOAC in this higher risk patient population.

Citations

Citations to this article as recorded by  
  • Welcome to the New JournalCardiovascular Prevention and Pharmacotherapy
    Mi-Jeong Kim, Jang-Whan Bae, Dae Ryong Kang
    Cardiovascular Prevention and Pharmacotherapy.2019; 1(1): 1.     CrossRef

CPP : Cardiovascular Prevention and Pharmacotherapy